Costa Rican Registry of IL-23 Inhibitors in Psoriatic Disease
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age12+
SponsorCaja Costarricense de Seguro Social
About this trial
The goal of this observational registry study is to evaluate the real-world effectiveness and safety of IL-23 inhibitors in patients with psoriatic disease (psoriasis and/or psoriatic arthritis) treated in Costa Rica. The main questions it aims to answer are:
* Do IL-23 inhibitors (guselkumab or risankizumab) improve disease severity and quality of life in patients with psoriatic disease in routine clinical practice? * What is the safety profile and treatment persistence of IL-23 inhibitors in this population? * Patients receiving IL-23 inhibitors as part of their usual medical care will be followed longitudinally using standardized clinical measures (e.g., PASI, DLQI, DAPSA/BASDAI) and adverse-event reporting through a national registry.
Eligibility criteria
Qualifiers
Confirmed diagnosis of psoriatic disease, including psoriasis (any clinical variant) and/or psoriatic arthritis based on rheumatologic criteria.
Receiving IL-23 inhibitor therapy (guselkumab or risankizumab).
Treated within participating Costa Rican public health centers.
Availability of sufficient clinical records to complete registry data (history, follow-up, labs).
Disqualifiers
None specified (all patients meeting inclusion criteria are eligible).
Trial design
Treatments tested in this trial
- Guselkumab (GUS)
- Risankizumab (RISA)
Treatment groups
No treatment groups listed
Sponsors and collaborators
Source ClinicalTrials.gov